CN Patent

CN112159392B — 取代嘧啶化合物及其药物组合物和该化合物的用途

Assigned to Nanjing Leizheng Pharmaceutical Technology Co ltd · Expires 2021-11-23 · 4y expired

What this patent protects

本发明涉及取代的嘧啶类化合物及其药物组合物和该化合物的用途。对突变EGFR和突变HER2具有优良的抑制活性，且具有通式(I)的取代的嘧啶类化合物及其药学上可接受的盐具有优良的药效学性能、代谢稳定性和/或更好的血脑屏障透过性。

USPTO Abstract

本发明涉及取代的嘧啶类化合物及其药物组合物和该化合物的用途。对突变EGFR和突变HER2具有优良的抑制活性，且具有通式(I)的取代的嘧啶类化合物及其药学上可接受的盐具有优良的药效学性能、代谢稳定性和/或更好的血脑屏障透过性。

Drugs covered by this patent

Patent Metadata

Patent number
CN112159392B
Jurisdiction
CN
Classification
—
Expires
2021-11-23
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing Leizheng Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.